Q-omics provides the consensus-scored CORO1C profile across patient tissues and cancer cell-line models. CORO1C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CORO1C is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CORO1C protein abundance shows 29,273 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where CORO1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORO1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORO1C survival associations across molecular data types. CORO1C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORO1C RNA expression–survival associations across cancer types. High CORO1C expression shows unfavorable associations in UVM, MESO, LIHC, HNSC, BLCA and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CORO1C RNA expression.
This table summarizes CORO1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CORO1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORO1C shows lower tumor expression in LUAD and BLCA and higher tumor expression in HNSC, KIRC, KIRP and THCA. The HNSC box plot shows higher CORO1C RNA expression in tumor versus normal tissue (log2 FC = +1.558, t-test p < 0.001).
This table shows molecular features associated with CORO1C in patient tissues and cancer cell lines. In patient samples, CORO1C shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CORO1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
